e-learning
resources
Vienna 2009
Monday, 14.09.2009
Animal models of airways inflammation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Co-treatment with clarithromycin and dexamethasone on murine mycoplasma pneumoniae pneumonia model
S. Hirao, H. Wada, S. I. Mikura, T. Saraya, D. Kurai, T. Akashi, K. Nakagaki, S. Kamiya, H. Goto (Mitaka, Musashino, Japan)
Source:
Annual Congress 2009 - Animal models of airways inflammation
Session:
Animal models of airways inflammation
Session type:
Thematic Poster Session
Number:
2098
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hirao, H. Wada, S. I. Mikura, T. Saraya, D. Kurai, T. Akashi, K. Nakagaki, S. Kamiya, H. Goto (Mitaka, Musashino, Japan). Co-treatment with clarithromycin and dexamethasone on murine mycoplasma pneumoniae pneumonia model. Eur Respir J 2009; 34: Suppl. 53, 2098
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of
mycoplasma pneumoniae
pneumonia
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008
Immunomodulating effect of clarithromycin in a murine model of
mycoplasma pneumoniae
pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 737s
Year: 2007
Treatment of patients with bronchial asthma and latent chlamydophila pneumoniae and mycoplasma pneumoniae infections by a doxycycline
Source: Eur Respir J 2002; 20: Suppl. 38, 159s
Year: 2002
Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia
Source: Eur Respir J 2010; 36: 969-971
Year: 2010
Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection in which Streptococcus pyogenes was isolated in sputum culture
Source: Eur Respir J 2004; 24: Suppl. 48, 414s
Year: 2004
Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to
legionella pneumophila
Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence
Year: 2004
Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model
Source: Eur Respir J 2005; 25: 693-700
Year: 2005
Corticosteroid therapy combined with antibiotics for severe Streptococcus pneumoniae pneumonia in ventilated piglets
Source: International Congress 2019 – Clinical challenges in respiratory infection
Year: 2019
Telavancin vs. linezolid in an animal model of severe MRSA pneumonia
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018
The efficacies of macrolides in a murine model of methicillin-resistant staphylococcus aureus hematogenous pulmonary infection
Source: Eur Respir J 2002; 20: Suppl. 38, 357s
Year: 2002
Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae
Source: Eur Respir J 2006; 27: 1020-1025
Year: 2006
Fast replicating strains of streptococcus pneumoniae are associated with severe community-acquired pneumonia
Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia
Year: 2009
Monitoring of
Mycoplasma pneumoniae
and
Chlamydia pneumoniae
in young patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2001; 18: Suppl. 33, 140s
Year: 2001
Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant
Mycoplasma pneumoniae
pneumonia in pediatric patients
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Severe
Chlamydia pneumoniae
community-acquired pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 545s
Year: 2003
Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia
Source: Eur Respir J 2016; 48: 1150-1159
Year: 2016
Delirium induced by clarithromycin in a patient with community-acquired pneumonia
Source: Eur Respir J 2006; 28: 671-672
Year: 2006
Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with pneumonia
Source: Eur Respir J 2001; 17: 241-245
Year: 2001
Long term treatment with azithromycin in chronic respiratory infections with
pseudomonas aeruginosa
Source: Eur Respir J 2006; 28: Suppl. 50, 558s
Year: 2006
The effects of fluticasone propionate in mice infected with Chlamydia pneumoniae
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept